Mirati Therapeutics' KRAZATI Faces Setback; Comerica Q2 Earnings Beat
- July 21st, 2023
- 375 views
Mirati Therapeutics, Inc. (Nasdaq: MRTX) faced a setback when the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Conditional Marketing Authorisation Application (MAA) for its drug KRAZATI (adagrasib), intended to treat patients with KRASG12C-mutated advanced non-small cell lung cancer (NSCLC).
According to the CHMP, KRAZATI exhibits a positive risk-benefit profile, but it does not fully meet specific requirements for obtaining Conditional Marketing Authorization. Mirati Therapeutics disagrees with the CHMP's opinion and plans to request a formal re-examination.
In pre-market, $MRTX was trading at $31.54, down $2.27 (-6.71%) following the announcement.
In other news, Comerica Incorporated (NYSE: CMA) released its second-quarter 2023 financial results, exceeding expectations with earnings per share (EPS) of $2.01 compared to the consensus estimate of $1.86.
$CMA was trading at $55.64 in pre-market, reflecting a gain of $2.71 (+5.12%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login